The Zydus Cadila vaccine for children above 12 are considered to give approval this week for emergency use by India’s drug regulator.
The regulator’s subject expert committee (SEC) will examine data submitted by Cadila.
The vaccine has been tested on adults as well as children above 12 and if the regulatory committee is satisfied with the submitted data and documents, the vaccine will be approved for emergency use soon, officials said. An approval can hasten the opening of schools although vaccine supply will remain a concern.
If the SEC finds the phase 3 data submitted by the company satisfactory, the emergency use authorization for the vaccine can be granted this week itself.
Discussion about this post